Gladys Morrison Email & Phone Number

North Chicago, Illinois, US

North Chicago, Illinois, US

North Chicago, Illinois, US

Cambridge, MA, US

• Responsible for reviewing and providing scientific input to clinical protocols, informed consents, investigator brochures and site initiation visit (SIV) slides
• Contribute to clinical data review plans, electronic case report form guidelines and subject enrollment forms
• Aiding in reviewing patient profiles, clinical data in the EDC and ensuring compliance to the clinical protocol
• Key contributor to the translational sciences program, in executing against the translational plan to support early decision-making as well in support against the CDx strategy.
• Working with program team leads to support the implementation and coordination of novel prognostic, pharmacodynamic biomarkers to enable science driven decisions
• Collaborating with several cross functional teams in business development, regulatory, market research and preclinical

Chicago, IL, US

• Managing immuno-oncology Phase I/II clinical trials.
• Involved in the overall clinical trial execution including study initiation visits (SIVs), patient visits, local and central laboratory PK/PD collections, accurate data entry, per-protocol collection of radiographic.
• Acting as the primary point of contact between sponsors, physicians, and patients, supporting continuous communication and trial progress.
• Working collaboratively with study monitors, sponsors, and principal investigators to ensure compliance with the approved standard operating procedures (SOPs), protocol/amendments, GCP, and the applicable regulatory.
• Performing data management activities through the initiation/updating of eCRF and query resolution in EDMS/CTMS.
• Present at data safety monitoring meetings on the scientific rationale and inclusion criteria of open clinical trials to help increase patient recruitment.

Evanston, IL, US

• Managing projects essential for characterizing the mechanism of action of novel NMDAR modulators in various rodent models of neurological disease
• Informing clinical trial outcome program lead for the compounds in our pipelineo Work with cross-functional team leads to establish timelines, communicate expectations, and report on project statuso Identify which.
• Communicate and establish relationships with outside CRO/vendorso Work to secure budget necessary for the initiation and completion of the projecto Ensure timely completion of projects by setting up follow-up meetings.
• Managing large datasetso Used multiple software platforms to identify NYX-compound mechanism of action via drug- and disease-specific proteomic profileso Streamlined and compiled all proteomic and transcriptomic studies
• Designed and executed studies to assess brain regions and signaling processes necessary for the analgesic effect of NYX-2925 in neuropathic paino Identified Src as potential regulator of the analgesic effect of.
• Improved and implemented departmental SOPs for immunoblotting to ensure assay reliability and reproducibility

Chicago, IL, US

• Stratifying and identifying novel compounds that result in greater inhibition of tumor growth than current standard of care in breast cancer
• Applied a novel computational algorithm capable of considering the expression of the whole transcriptome for breast cancer tumor expression data from the cancer genome atlas (TCGA) to predict various drugs’ sensitivity.
• Identified and validated biomarkers that predict sensitivity to novel agents using enrichment analysis
• Evaluated correlation between capecitabine response in patient-derived ex vivo model and patient
• Performed high-throughput drug screens to discover novel agents that can overcome chemotherapy induced peripheral neuropathy using patient-derived peripheral neurons
• Presented research and study data at meetings and conferences.

Houston, Texas, US

Circumventing Breast cancer endocrine resistance where the HER pathway becomes up-regulated and drives resistance.My studies looked into combining endocrine therapy with a novel HER1/2 tyrosine kinase inhibitor to overcome endocrine resistance or to delay endocrine resistance onsetA side project evaluated and characterized the tumor initiating cell.

Atlanta, GA, US

Houston, Texas, US

8week summer program in which i worked with Dr Debananda Pati, to understand the mechanism of cohesion complex during cell division.

Doctor Of Philosophy (Ph.D.), Translational Biology And Molecular Medicine

Bachelor Of Science (B.S.), Biochemistry

Education record